ABIONYX Pharma S.A.
ABNX.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €2 | €2 | €2 | €3 |
| % Growth | -6% | -3.8% | -6.7% | – |
| Cost of Goods Sold | €2 | €2 | €2 | €2 |
| Gross Profit | €0 | €1 | €0 | €1 |
| % Margin | 10.8% | 26.5% | 12.9% | 25% |
| R&D Expenses | €1 | €2 | €1 | €2 |
| G&A Expenses | €0 | €0 | €0 | €0 |
| SG&A Expenses | €2 | €2 | €2 | €1 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | -€0 | €0 | €0 | -€1 |
| Operating Expenses | €3 | €3 | €3 | €2 |
| Operating Income | -€2 | -€2 | -€3 | -€1 |
| % Margin | -109.9% | -103.8% | -110.4% | -47.1% |
| Other Income/Exp. Net | €0 | €0 | €0 | -€0 |
| Pre-Tax Income | -€2 | -€2 | -€3 | -€1 |
| Tax Expense | €0 | -€1 | -€0 | €0 |
| Net Income | -€2 | -€2 | -€2 | -€1 |
| % Margin | -108.5% | -101.6% | -89.1% | -50.6% |
| EPS | -0.067 | -0.066 | -0.065 | -0.041 |
| % Growth | -0.6% | -2% | -59.2% | – |
| EPS Diluted | -0.067 | -0.066 | -0.065 | -0.041 |
| Weighted Avg Shares Out | 35 | 35 | 32 | 31 |
| Weighted Avg Shares Out Dil | 35 | 35 | 32 | 31 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €4 | €0 | €0 |
| EBITDA | -€2 | €2 | -€2 | -€1 |
| % Margin | -107.4% | 90.9% | -97.7% | -45.3% |